|1.||Andries, Koen: 20 articles (08/2014 - 01/2005)|
|2.||Lounis, Nacer: 10 articles (08/2014 - 01/2005)|
|3.||Jarlier, Vincent: 6 articles (01/2011 - 01/2005)|
|4.||Andries, K: 4 articles (06/2012 - 03/2007)|
|5.||Gevers, Tom: 4 articles (03/2012 - 10/2008)|
|6.||Guillemont, Jerome: 4 articles (01/2011 - 01/2005)|
|7.||Veziris, Nicolas: 4 articles (01/2011 - 11/2006)|
|8.||Truffot-Pernot, Chantal: 4 articles (09/2009 - 01/2005)|
|9.||Diacon, Andreas H: 3 articles (08/2014 - 06/2009)|
|10.||Lounis, N: 3 articles (06/2012 - 03/2007)|
01/01/2011 - "The experimental compound TMC207 is showing promise against infections caused by Mycobacterium tuberculosis both in a variety of animal studies and in the field. "
06/01/2010 - "Current and future studies will determine the role of TMC207 in a shortened treatment regimen for drug-sensitive TB, a more effective and better-tolerated regimen for MDR-TB, the treatment of latent TB infection, and intermittent-TB treatment regimens."
03/01/2012 - "tuberculosis and following administration of different doses of TMC207 at various dosing frequencies for 6 weeks starting 2 weeks after infection. "
11/01/2009 - "The efficacy of ATP synthase inhibitor TMC207 was assessed in early and late Mycobacterium avium infections in mice. "
03/01/2012 - "The pharmacokinetic and pharmacodynamic (PK-PD) response was investigated in the murine model of tuberculosis (TB) infection following oral administration of different doses of TMC207 or N-desmethyl TMC207 at 5 days per week for 4 weeks starting the day after intravenous infection with M. "
03/01/2013 - "Diarylquinoline compounds are newly synthesized derivatives of the new anti-tuberculosis drug, TMC207. "
11/01/2012 - "Synergy between two new antimycobacterial compounds, such as TMC207 and BTZ043, with novel targets, offers an attractive foundation for a new tuberculosis regimen."
11/01/2012 - "tuberculosis than TMC207 alone at a concentration of 80 ng/ml. This synergy was not observed when the combination was tested on a BTZ-resistant M. "
03/01/2012 - "Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis."
01/01/2011 - "The diarylquinoline TMC207 is a highly promising drug candidate for treatment of tuberculosis. "
09/01/2007 - "Most importantly, the few remnants of acid-fast bacilli remaining after R207910 treatment were to be found extracellular, in a microenvironment of residual primary lesion necrosis with incomplete dystrophic calcification. "
01/01/2011 - "In this study, we used the guinea pig model, a species that shows several similarities to human tuberculosis, including the hallmark of primary granuloma necrosis, to determine the efficacy of a combination regimen combining TMC207 with rifampin and pyrazinamide. "
|5.||Leprosy (Hansen's Disease)
|4.||Adenosine Triphosphate (ATP)
|6.||1- (6- bromo- 2- methoxy- quinolin- 3- yl)- 4- dimethylamino- 2- (3- fluorophenyl)- 1- phenyl- butan- 2- ol (R207910)
|1.||Drug Therapy (Chemotherapy)